“At the national level, it is a systematic process to integrate traditional Chinese medicine into the (prevention and treatment) system of infectious diseases in the whole country and let traditional Chinese medicine participate in the whole process of management, including flow regulation, monitoring, decision-making, planning, prevention and research.” Recently, Zhao Chao, deputy to the National People’s Congress and Shandong Buchang Pharmaceuticals Co.Ltd(603858) president, said in an interview with Zhongxin Jingwei that in order to make traditional Chinese medicine play a better role, it is suggested to incorporate the relevant contents of traditional Chinese medicine into the law on the prevention and treatment of infectious diseases. “From the long-term development of traditional Chinese medicine, we should increase the training of talents in the fields of infectious diseases and severe treatment, especially encourage medical personnel to exercise at the grass-roots level and rotate regularly to improve clinical diagnosis and treatment skills.”
on traditional Chinese medicine: incorporated into the national infectious disease prevention and control system
Zhao Chao observed that in the past two years, traditional Chinese medicine has become an important part of the “Chinese method” of anti epidemic. In particular, the core role of traditional Chinese medicine in the treatment of covid-19 pneumonia is to effectively reduce the weight conversion rate. Early intervention can significantly reduce the probability of mild patients developing into severe patients.
Data show that among the confirmed cases of covid-19 pneumonia in China, 74187 people used traditional Chinese medicine, accounting for 91.5%, of which 61449 people in Hubei Province used traditional Chinese medicine, accounting for 90.6%. Clinical efficacy observation shows that the total effective rate of traditional Chinese medicine has reached more than 90%.
However, Zhao Chao clearly pointed out that at present, the routine of traditional Chinese medicine has not been incorporated into the national infectious disease prevention and control system, and the state has not established the research system of traditional Chinese medicine epidemic prevention. None of the infectious disease hospitals in China is a traditional Chinese medicine hospital that can treat infectious diseases and a traditional Chinese medicine research institution that studies infectious diseases, When covid-19 pneumonia occurred, TCM medical institutions could only participate in some clinical and research work in the form of cooperative units.
In this regard, Zhao Chao put forward four suggestions. First, the guiding principles and Implementation Measures on further promoting equal emphasis on traditional Chinese and Western medicine were issued to implement the main role of the government. In the form of laws and regulations, determine the proportion of government funds for traditional Chinese medicine at all levels in the funds for health undertakings, ensure that the financial funds for traditional Chinese medicine are in place, and especially increase the construction of traditional Chinese medicine medical institutions in grass-roots communities.
Second, select and focus on the construction of designated clinical medical institutions for the prevention and treatment of infectious diseases with traditional Chinese medicine, and the state will give key support to establish a research system for infectious diseases with traditional Chinese medicine.
Third, optimize the work plan of traditional Chinese medicine for the prevention and treatment of infectious diseases, and establish a strong leadership decision-making mechanism and expert consultation mechanism.
Fourth, in the national scientific research and innovation system, effectively improve the proportion of investment in traditional Chinese medicine research. Zhao Chao also said that in the process of traditional Chinese medicine science and technology evaluation system, scientific and technological achievements evaluation and talent evaluation, highlight the social welfare characteristics of its scientific research, focus on the quality of scientific research achievements and social contribution, and focus on industrial users and social evaluation.
talking about innovative drugs: exploring the transformation of drug access from “invitation system” to “declaration system”
It is understood that in recent years, the national pharmaceutical industry has developed rapidly. From January to October 2021, China Meheco Group Co.Ltd(600056) pharmaceutical industry’s operating revenue was 235298 billion yuan, with a year-on-year increase of 22.8%, and the total profit of pharmaceutical manufacturing industry increased by 76.7%.
Zhao Chao also pointed out that at present, there are many shortcomings in the development of China Meheco Group Co.Ltd(600056) industry, including the lagging development of traditional Chinese medicine, the imbalance of the proportion of pharmaceutical structure, the lack of scientific and innovative ability, the poor effect of intelligent agglomeration and the need to enhance international competitiveness.
\u3000\u3000 Second, the incentive mechanism of “drug price reduction and innovation” of the current medical insurance company is still insufficient, but the incentive of “short-term medical insurance personnel” is still limited by the lack of long-term medical insurance innovation, which is not conducive to the improvement of the efficiency of drug R & D, and it is still limited by the short-term benefits of the current medical insurance company Perfect. ” Zhao Chao pointed out.
In this regard, Zhao Chao suggested introducing expert resources to support the training of drug trial personnel, including stable investment, expanding the personnel team of drug trial center and improving the overall professional ability and efficiency of drug trial; Implement the expert advisory committee mechanism, establish overseas review expert consultation channels, establish normalized consultation channels for new drug clinical trials, innovative drug approval and priority review, integrate China’s foreign drug review expert resources, and strengthen the training of drug review personnel.
Secondly, he proposed to optimize the bidding rules and reasonably determine the negotiation price of medical insurance, including reasonably planning the decline of drugs. While speeding up the clearance of “low-quality and ineffective” drugs and further promoting the price reduction of generic drugs, it is suggested to consider the actual production cost of drugs and reasonably determine the purchase price.
Moreover, for innovative drugs, Zhao Chao suggested that full consideration should be given to the different life cycles of drugs and certain price reduction protection should be given to protect the enthusiasm for innovation; Explore the transformation of drug access from “invitation system” to “declaration system”, and speed up the entry of innovative drugs into medical insurance.
Finally, Zhao Chao proposed that after the listing of new drugs, enterprises can apply for medical insurance without waiting for the medical insurance negotiation time window, so as to realize “enterprise rolling application, medical insurance rolling review and constant updating of the catalogue”, so that patients can use new drugs with significant clinical value as soon as possible.
